1 week Ago By Defense World Staff
Teacher Retirement System of Texas lifted its stake in shares of ImmunityBio, Inc. ( NASDAQ:IBRX – Free Report ) by 20.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission.
The firm owned 41,742 shares of the company’s stock after purchasing an additional 7,067 shares during the period. Teacher Retirement System of Texas’ holdings in ImmunityBio were worth $107,000 at the end of the most recent quarter. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company.
Intech Investment Management LLC grew its position in ImmunityBio by 54.7% during the fourth quarter. Intech Investment Management LLC now owns 105,386 shares of the company’s stock valued at $270,000 after purchasing an additional 37,246 shares in the last quarter.
Clearwater Capital Advisors LLC increased its stake in shares of ImmunityBio by 75.4% in the fourth quarter. Clearwater Capital Advisors LLC now owns 846,419 shares of the company’s stock worth $2,167,000 after acquiring an additional 363,870 shares during the last quarter.
Cibc World Markets Corp purchased a new stake in shares of ImmunityBio during the fourth quarter worth $35,000. Copperwynd Financial LLC raised its holdings in shares of ImmunityBio by 99.1% during the fourth quarter.
Copperwynd Financial LLC now owns 20,087 shares of the company’s stock worth $51,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its stake in ImmunityBio by 40.7% in the fourth quarter.
Commonwealth Equity Services LLC now owns 28,955 shares of the company’s stock valued at $74,000 after purchasing an additional 8,380 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.
Analysts Set New Price Targets IBRX has been the subject of a number of recent analyst reports. BTIG Research initiated coverage on ImmunityBio in a research report on Friday, January 10th. They issued a “buy” rating and a $6.
00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of ImmunityBio in a report on Thursday, March 13th.
Finally, D. Boral Capital restated a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a research note on Monday.
One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.19.
ImmunityBio Trading Up 3.0 % Shares of NASDAQ:IBRX opened at $3.05 on Thursday.
The business has a 50-day moving average price of $3.12 and a two-hundred day moving average price of $3.59.
ImmunityBio, Inc. has a 1-year low of $2.28 and a 1-year high of $10.
53. The stock has a market capitalization of $2.60 billion, a P/E ratio of -3.
32 and a beta of 0.82. ImmunityBio ( NASDAQ:IBRX – Get Free Report ) last issued its earnings results on Monday, March 3rd.
The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.
11. The firm had revenue of $7.55 million during the quarter, compared to the consensus estimate of $8.
74 million. As a group, equities analysts predict that ImmunityBio, Inc. will post -0.
92 EPS for the current year. About ImmunityBio ( Free Report ) ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Read More Five stocks we like better than ImmunityBio Overbought Stocks Explained: Should You Trade Them? Homebuilders in Freefall: Bargain Opportunity or Falling Knife? How to Use the MarketBeat Stock Screener The 3 Most Talked About Investments on WallStreetBets Right Now How to Know if a Stock Pays Dividends and When They Are Paid Out Analyst Targets Signal More Growth in CrowdStrike Stock Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. ( NASDAQ:IBRX – Free Report ).
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter ..
_0.jpg?itok=Jn8RJQZW)
